Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives $39.00 Average PT from Analysts

Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) have been assigned a consensus recommendation of “Moderate Buy” from the seven ratings firms that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $37.71.

Several research firms have recently weighed in on AKRO. UBS Group upped their price objective on Akero Therapeutics from $39.00 to $42.00 and gave the company a “buy” rating in a research note on Tuesday, March 5th. Bank of America began coverage on Akero Therapeutics in a research note on Monday. They issued a “neutral” rating and a $30.00 price objective on the stock. Finally, HC Wainwright upped their price objective on Akero Therapeutics from $40.00 to $43.00 and gave the company a “buy” rating in a research note on Friday, March 1st.

Akero Therapeutics Trading Down 3.5 %

Akero Therapeutics stock opened at $20.26 on Friday. The business has a 50 day moving average price of $24.73 and a two-hundred day moving average price of $20.98. The company has a quick ratio of 29.27, a current ratio of 29.27 and a debt-to-equity ratio of 0.05. The stock has a market cap of $1.40 billion, a price-to-earnings ratio of -7.11 and a beta of -0.38. Akero Therapeutics has a 12 month low of $11.25 and a 12 month high of $58.38.

Akero Therapeutics (NASDAQ:AKRO) last posted its quarterly earnings results on Thursday, February 29th. The company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.17). As a group, equities analysts forecast that Akero Therapeutics will post -4.06 EPS for the current year.

Insider Buying and Selling

In related news, COO Jonathan Young sold 5,000 shares of the stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $24.38, for a total transaction of $121,900.00. Following the sale, the chief operating officer now directly owns 263,306 shares in the company, valued at approximately $6,419,400.28. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In related news, COO Jonathan Young sold 5,000 shares of the stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $24.38, for a total transaction of $121,900.00. Following the sale, the chief operating officer now directly owns 263,306 shares in the company, valued at approximately $6,419,400.28. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Catriona Yale sold 20,646 shares of the stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $35.49, for a total value of $732,726.54. Following the sale, the insider now owns 78,415 shares in the company, valued at $2,782,948.35. The disclosure for this sale can be found here. Insiders have sold a total of 100,646 shares of company stock worth $3,319,877 in the last three months. Insiders own 9.69% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of AKRO. SG Americas Securities LLC boosted its position in Akero Therapeutics by 139.6% in the 3rd quarter. SG Americas Securities LLC now owns 19,134 shares of the company’s stock valued at $968,000 after buying an additional 11,148 shares during the last quarter. Peregrine Capital Management LLC bought a new position in Akero Therapeutics in the 3rd quarter valued at $4,828,000. Bank of New York Mellon Corp boosted its position in Akero Therapeutics by 225.0% in the 3rd quarter. Bank of New York Mellon Corp now owns 500,245 shares of the company’s stock valued at $25,302,000 after buying an additional 346,317 shares during the last quarter. Miracle Mile Advisors LLC acquired a new position in shares of Akero Therapeutics in the 3rd quarter valued at $238,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Akero Therapeutics by 26.8% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,878 shares of the company’s stock valued at $500,000 after purchasing an additional 2,090 shares during the period.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.